Allergan PLC will pay Acelity LP Inc. $2.9bn to buy the LifeCell Corp. portfolio of aesthetic and surgical products. The all-cash deal not only marks Allergan’s first regenerative medicine transaction – and one that is accretive to the specialty pharma company's top- and bottom-line, it will also provide Acelity with an alternative source of new capital now that the firm has finally quashed its long-held hopes for an IPO.
The LifeCell purchase gives Allergan a suite of commercial products for what chief commercial officer William Meury describes as the company’s “most important customer” – plastic surgeons.
“With the acquisition of LifeCell, we probably have the largest and most focused business for aesthetics and plastic surgery,” Meury said in an interview with Medtech Insight's sister publication Scrip.